Excited to share our new work in Science Immunology! We describe targeting of gut-associated lymphoid tissue (GALT) as a novel mode of action of anti-α4β7 therapy in IBD. Co-led by Mathieu Uzzan & A. Seki Mehandru Lab @MountSinai Lipschultz Precision Immunology Institute Mount Sinai Division of Gastroenterology Icahn School of Medicine at Mount Sinai🧵
science.org/doi/10.1126/sc…

Celiac disease is a chronic immune-mediated enteropathy that may be unleashed by enteric viral infections.

Recent findings in mice identified protist Tritrichomonas arnold protects against viral-induced gluten intolerance:

gutmicrobiotaforhealth.com/protist-tritri…

Interesting read: Major data analysis errors invalidate cancer microbiome findings | mBio journals.asm.org/doi/10.1128/mb…

Very impressive and high value work. “Integrated annotation prioritizes metabolites with bioactivity in inflammatory bowel disease” #IBD

Welcoming 28 nationalities in the coming days IBD Leuven to disseminate #IUS among many #IBD specialists around the world for the benefit of our patients. Many thanks to the fantastic InternationalBowelUS team, (inter)national faculty and patients to make this happen! #unitedwestand

Delighted to see 🇬🇧 PANTS study 3 year extension data published in The Lancet Gastroenterology & Hepatology
🙏🏼 to the investigators and patients who participated
sciencedirect.com/science/articl…

⏺️Only 1/3 of those treated with TNFis remain in remission at 3years
⏺️Week 14 levels significant in reducing

Can’t wait to ✈️ to Belgium today to continue to teach intestinal ultrasound to a new group of IBD experts from around the world!

So excited to partner with the ICN PAC for “Empowering Appointment Preparation and Navigation” & w/ my MassGeneralChildren IBD Center team on Assessing Mucosal Healing with Regular Stool Calprotectin Levels.
Hope to see you there!!!

Well deserved. A true testament to what happens when good science is done by good people who genuinely care and partner with patients/caregivers.

A few critical observations.

Good idea for a study but I don’t particularly like treatment persistence as the main endpoint, particularly in patients who have essentially run out of options. Moreover, a possible 3 or 6 week longer persistence of one drug as 4th line (but not

For me, the headline is that vedolizumab is safer than immunomodulators, combo therapy and no immunosuppression (see confidence intervals).

Reminder. Please RT

The future of gut microbiome manipulation in medicine laid out here is remarkable
sciencedirect.com/science/articl… William Fusco ElinavLab Gianluca Ianiro Giovanni Cammarota Hugh Thomas The Lancet Gastroenterology & Hepatology

Sooner: yes. “Aggressively”: no. We never use “aggressive” treatment in #IBD We know the risk/benefit ratio, we evaluate every #patient with great care. Of course we can make mistakes, but we try avoiding any “aggressiveness” iris dotan GETECCU #Crohn #UlcerativeColitis

Eavesdropping on colitis, cell by cell answers.childrenshospital.org/colitis-intest…
#IBD

EEN is one of the best treatment options available to people with #CrohnsDisease .

.Dale Lee, Kimberly Braly & colleagues found a whole-foods smoothie mimics commercial oral milkshakes for inducing clinical & biochemical remission in children with active CD.

[🧵 inside]

This discovery will have a significant impact on patients with this rare mutation - more VUS to reclassify!
Response to JAKi tbd???
Always great working with Harry Layton Lesmana, MD, FAAP, FACMG !

Interesting signal here, aligns with other studies relevant to #IBD ;
“In New York City from 1993 to 2010, CD-related death rates were higher among individuals from neighborhoods with higher levels of SO2”
tinyurl.com/ye28y2hs

#GUTImage from the paper by Guo et al entitled

'Early-life diet and risk of inflammatory bowel disease: a pooled study in two Scandinavian birth cohorts' via

bit.ly/3IHYPAY

#IBD #Diet

A 24yo male with ileal CD in clinical remission on biologic monotherapy presents for disease assessment with IUS following normal colonoscopy. IUS features suggest he needs treatment escalation or switch of medical therapy. What are the features of active inflammation?